Truqap is a kinase inhibitor that actually works by blocking pathways that support the cancer cells endure and develop, so reduces most cancers progress. Truqap is from a class of medicines referred to as an AKT inhibitor. Truqap obtained FDA acceptance on November 17, 2023, after optimistic outcome